ArticleCell communication and signaling : CCS2025
Tankyrases modulate the hypoxia response through non-catalytic mechanisms affecting HIF-1α.
Article in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metabolic reprogramming in cancer: dysregulation of glucose, lipid, and amino acid pathways and therapeutic opportunities.Molecular biomedicine · 2026Review
- Immunometabolic reprogramming in rheumatoid arthritis: the epitranscriptomic role of N6-methyladenosine in innate and adaptive immunity.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAdaptation to hypoxia is essential for cancer survival and is linked to poor prognosis and treatment resistance. This adaptation triggers the expression of genes that promote angiogenesis and metabolic reprogramming, collectively enhancing cancer cell survival, tumor growth, migration and metastasis. Consequently, there is an urgent need for innovative strategies to inhibit tumor adaptation to hypoxic conditions.
methodsThe public database cBioPortal was utilized to analyze tankyrase mRNA alteration profiles across various cancer types, and the correlation between TNKS/2 and HIF1A expression was assessed using the GEPIA platform. The effects of TNKS1/2 inhibition or silencing on HIF-1α stabilization and activation were evaluated through western blotting and RT-qPCR analysis of HIF-target genes. To gain a comprehensive understanding of the impact of tankyrase elimination on hypoxia-driven gene expression, RNA-seq was also conducted. The effects on cell fitness and the functional consequences of tankyrase silencing in tumor cell adaptation to hypoxia were examined by measuring glycolysis through ECAR and lactate assays, along with apoptosis, colony formation and migration and invasion assays. To elucidate the molecular mechanisms by which tankyrases influence hypoxic signaling, we employed a range of approaches, including polysome profiling, mRNA half-life assays, reporter luciferase assays to analyze the HIF-1α promoter, and proximity ligation assays to explore the effect of tankyrase elimination on the interaction between HIF-1α and its inhibitory protein FIH-1.
resultsIn the present study, we investigated the role of TNKS1 and TNKS2 as modulators of the hypoxic response. Notably, we found that tankyrases participate in the regulation of both HIF-1α levels (through fine-tuning HIF1A mRNA expression) and hypoxia-induced gene expression (through alteration of HIF-1α binding to FIH-1). Global RNA-seq revealed a specific impairment of the hypoxia-induced metabolic switch to glycolysis, with consequences for metabolic adaptation and cell fitness following TNKS1/2 silencing. These effects were independent of tankyrase catalytic activity.
conclusionOur findings reveal a novel role for tankyrases in regulating tumor cell adaptation to hypoxia. This new mechanism operates independently of their catalytic activity, underscoring the potential of strategies that target tankyrases interaction with multiple partners through the ankyrin domain and holding promise for the development of new therapeutic advances to counter tumor adaptation to hypoxia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.